Newsletter
| Promoter: | SecretStockPromoter | Paying Party: | Emedia advisors |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| ENDV | $14000 | UNKNOWN |
| Max Profit: 5.49 % | Gain at close: 0.00 % | |
| *We think that this promoter is a part of a group of promoters. | ||
Tomorrow's Breakout Alert is: ENDV
Secret Stock Members,
Congrats to everyone that profited from our most recent alert, which rallied 42 percent (from .24 to .34) in just 3 trading sessions last week.
It’s time to add another pick to the Winner’s Circle
We teased you about our Biotech Alert on Friday and are of the belief that this Pick could force a potential rally over the next week and is being hailed as OUR PULLBACK PLAY OF THE SUMMER.
Amazing trading opportunities don’t always appear super obvious, which is why it’s so critical that you learn to look beyond the ticker tape.
We are under the impression that many shorts sold out of their long-held positions on Friday creating this dip and potential Momentous Play back up the charts.
This presents a Huge Bounce Opportunity for traders right now. This biotech pick has proven capable of big moves in the past, and with momentum building the past 2 sessions, the potential gains could be even bigger than 42 percent.
Because of this…
I Am Issuing An Immediate Alert For Endonovo Therapeutics Inc. (ENDV)
Building on electromagnetic technologies, like MRI and CAT, which are universally applicable and reliable, ENDV is taking the concept of the fundamental and universal validity and reliability of accessing biology at the electromagnetic level, into the therapeutic realm.
According to BCC Research, the global liver therapeutics market totaled nearly $24.5Bn in 2014 and is projected to approach 33.8Bn by 2019, registering a compound annual growth rate (CAGR) of 6.7-percent through 2019.
ENDV announced earlier this year that they are about to start pre-clinical testing for their electroceutical technology. A development like this could send the valuation of ENDV soaring.
There is a huge market opportunity for ENDV.
The American Liver Foundation estimates that up to 30 percent of the US population is affected by non-alcoholic fatty liver disease.
With such a low float and shorts hopefully getting out of the way on Friday we could see some Major Action tomorrow.
Do your homework this evening and set those alarm clocks for Monday as we focus our investor attention on the pullback potential of ENDV.
About Endonovo Therapeutics, Inc.
Incorporated in 2011 and headquartered in Woodland Hills, CA, Endonovo Therapeutics, Inc. is a biotechnology company which develops cell-based therapies and non-invasive bioelectronic therapies to enhance the human life through regenerating tissues and organs. It is developing therapies for various inflammatory, autoimmune, and degenerative diseases using cell therapies and time-varying electromagnetic fields.
Endonovo Therapeutics Targets Non-Invasive Treatment for Acute and Chronic Inflammatory Conditions of the Liver
Earlier this year, on April 8, 2015, ENDV announced its intention to begin pre-clinical testing of its electroceutical technology to treat and reverse acute and chronic inflammatory liver pathologies. This includes the conditions that cause nonalcoholic steatohepatitis (NASH) and human cirrhotic liver disease.
The American Liver Foundation estimates that up to 30 percent of the U.S. population is affected by non-alcoholic fatty liver diseases, including NASH and other obesity related liver ailments.
Alan Collier, CEO and Chairman of ENDV, commented, "We believe Endonovo's proprietary electroceutical technology holds great promise for the treatment of inflammatory conditions of hepatic origin, furthermore addressing NASH and human cirrhotic liver disease with a non-invasive and safe medical device.”
Technical Indicators:
ENDV has proven capable of rapid advances in the past and could be in for yet another big move to the upside very soon.
In fact, just last month on July 13, ENDV saw double-digit intraday gains, opening at just above 0.50 per share to reach a day’s high of 0.73 per share for a nearly 45-percent single day advance.
Pulling back since then, ENDV closed in the last session at just 0.45 per share, and could now be presenting a window of opportunity for investors ahead of a potential reversal in the sessions to come.
Trading more than 300K shares in the last session alone, more than 7 times its 3 Month Average Volume of just under 41K shares, ENDV could quickly gain the momentum it needs to see another rapid move to the upside very soon.
ENDV growth potential is massive, and given the recent pullback could prove to be incredibly undervalued.
The Biotech sector has delivered significant gains this year, outperforming the rest of the market and ENDV could be the next standout within an already red hot sector.
The company is taking a truly revolutionary approach to therapeutics and as it continues to develop its technologies there’s no telling how much and how fast it can grow.
As always, please do you own research this evening and keep a close eye on ENDV throughout the week.
Yours truly,
Jeff Thompson
SecretStockPromoter
Disclaimer:
SecretStockPromoter is engaged in the business of marketing and advertising companies. All content in this communication is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Never invest in any stock featured in the SecretStockPromoter email alerts unless you can afford to lose your entire investment. Many of the stocks featured are highly volatile and speculative in nature.
Compensation: We have been compensated Fourteen Thousand Dollars by a third party, Emedia Advisors LLC, for this publication regarding Endonovo Therapeutics, Inc. (ENDV). We do not own any shares of ENDV.
Neither Jeff Thompson or any of the SecretStockPromoter employees are registered as investment advisors, financial analysts, brokers, or dealers in any jurisdiction whatsoever. Your use of the SecretStockPromoter email alerts, means that you agree to hold SecretStockPromoter, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation for the purchase or sale of any securities. The information provided is obtained from sources deemed reliable, but SecretStockPromoter does not guarantee in any way the timeliness, sequence, accuracy, adequacy, or completeness of such information made regarding stocks discussed in SecretStockPromoter email alerts.
The owner, publisher, editor and their associates are not responsible for errors and omissions. You understand and agree that at the time of any transaction you make, SecretStockPromoter employees, SecretStockPromoter affiliates, and friends and family of Jeff Thompson and SecretStockPromoter owners and operators may have a position in such securities. The position may have been acquired prior to the publication of any website information or email alert. You should also be aware that the aforementioned parties do have the right to sell their positions at any time without further notification. Any opinions expressed are subject to change without notice SecretStockPromoter encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or persons affiliated with or associated with such companies; or is available from public sources.
SecretStockPromoter is engaged in the business of marketing and advertising companies. All content in this communication is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Never invest in any stock featured in the SecretStockPromoter email alerts unless you can afford to lose your entire investment. Many of the stocks featured are highly volatile and speculative in nature.
Compensation: We have been compensated Fourteen Thousand Dollars by a third party, Emedia Advisors LLC, for this publication regarding Endonovo Therapeutics, Inc. (ENDV). We do not own any shares of ENDV.
Neither Jeff Thompson or any of the SecretStockPromoter employees are registered as investment advisors, financial analysts, brokers, or dealers in any jurisdiction whatsoever. Your use of the SecretStockPromoter email alerts, means that you agree to hold SecretStockPromoter, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation for the purchase or sale of any securities. The information provided is obtained from sources deemed reliable, but SecretStockPromoter does not guarantee in any way the timeliness, sequence, accuracy, adequacy, or completeness of such information made regarding stocks discussed in SecretStockPromoter email alerts.
The owner, publisher, editor and their associates are not responsible for errors and omissions. You understand and agree that at the time of any transaction you make, SecretStockPromoter employees, SecretStockPromoter affiliates, and friends and family of Jeff Thompson and SecretStockPromoter owners and operators may have a position in such securities. The position may have been acquired prior to the publication of any website information or email alert. You should also be aware that the aforementioned parties do have the right to sell their positions at any time without further notification. Any opinions expressed are subject to change without notice SecretStockPromoter encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or persons affiliated with or associated with such companies; or is available from public sources.
Galaxy, LLC.|18685 Main St STE 101-403 | Huntington Beach, CA 92646